Therefore, the use of these inhibitors could counteract the positive ERα36/EGFR loop in the progression of triple-negative breast tumors or the ER36/EGFR/HER2 loop in tamoxifen resistance within ERα66–positive breast tumors. Here, ERBB2 is linked to breast neoplasm.